Long Term Immune Response Produced by the SputnikV Vaccine

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• The SputnikV vaccine, developed by the Gamaleya National Research Centre, targets SARS-CoV-2.
• While effective, the precise immunological mechanisms of SputnikV remain incompletely understood.

Purpose of the Study:

• To map immunogenic domains of the SARS-CoV-2 spike (S) protein recognized by SputnikV-induced antibodies.
• To analyze cytokine profiles in vaccinated individuals and compare them with convalescent COVID-19 patients.

Main Methods:

• Utilized an overlapping peptide library to identify antibody binding sites on the SARS-CoV-2 S protein.
• Analyzed serum samples from 40 SputnikV-vaccinated individuals and convalescent COVID-19 patients.
• Assessed cellular immunity through T cell activation markers.

Main Results:

• Antibodies from SputnikV recipients and COVID-19 survivors recognized multiple S protein domains, including Receptor Binding Domain (RBD), N-terminal Domain (NTD), Fusion Protein (FP), and Heptad Repeats (HRs).
• Recognized epitopes were conserved across circulating SARS-CoV-2 variants.
• Humoral and cellular immune responses persisted for at least 90 days post-vaccination, indicating a durable effect.

Conclusions:

• SputnikV elicits a broad antibody response targeting conserved regions of the SARS-CoV-2 S protein.
• The vaccine induces a prolonged and potent immune response, evidenced by both humoral and cellular immunity (T cell activation).
• Findings support SputnikV's efficacy against SARS-CoV-2 and its variants.